Deaths in cancer trials remain mystery for promising therapy

December 04, 2016

CAR t-cell

The experimental CAR T-cell immunotherapy has shown dramatic results, including long-term cures, for cancer patients with severe disease, but has also left puzzling questions about deaths that have occurred during some tests, Bloomberg reports in a story published by The Washington Post.

“It’s a double-edged sword,” Lewis Silverman, clinical director of Dana-Farber/Boston Children’s Hematologic Malignancy Center, tells Bloomberg. “You have to get through some bad side effects because that’s actually a sign that the CAR-T is doing something.”

  • Read the story. Other outlets that picked up the story include the Chicago Tribune and News OK (The Oklahoman).

Media Inquiries

Peter Cohenno

Follow Us!

Our Twitter handle is:

Twitter Logo